These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 17638852)

  • 21. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
    Yumeen S; Girardi M
    Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
    Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma.
    Rea B; Haun P; Emerson R; Vignali M; Farooqi M; Samimi S; Elenitsas R; Kirsch I; Bagg A
    J Clin Pathol; 2018 Sep; 71(9):814-820. PubMed ID: 29636372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.
    Gjerdrum LM; Woetmann A; Odum N; Burton CM; Rossen K; Skovgaard GL; Ryder LP; Ralfkiaer E
    Leukemia; 2007 Dec; 21(12):2512-8. PubMed ID: 17713545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma.
    Gibbs JD; Ma S; Kim A; Seminario-Vidal L; Sokol L; Zhang H; Zhang X; Sagatys E; Chen PL; Messina JL
    Oncol Rep; 2021 Jan; 45(1):349-358. PubMed ID: 33416132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
    J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
    Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
    Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides.
    Dong Z; Zhu X; Li Y; Gan L; Chen H; Zhang W; Sun J
    Medicine (Baltimore); 2018 May; 97(21):e10871. PubMed ID: 29794791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
    Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
    Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).
    Litvinov IV; Netchiporouk E; Cordeiro B; Doré MA; Moreau L; Pehr K; Gilbert M; Zhou Y; Sasseville D; Kupper TS
    Clin Cancer Res; 2015 Jun; 21(12):2820-9. PubMed ID: 25779945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
    Fivenson DP; Hanson CA; Nickoloff BJ
    J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: a study of 12 cases.
    Marrogi AJ; Khan MA; Vonderheid EC; Wood GS; McBurney E
    J Cutan Pathol; 1999 Sep; 26(8):369-78. PubMed ID: 10551408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma.
    Miyagaki T; Sugaya M; Suga H; Akamata K; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2012 Jul; 304(5):401-6. PubMed ID: 22526325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures.
    Herrera A; Cheng A; Mimitou EP; Seffens A; George D; Bar-Natan M; Heguy A; Ruggles KV; Scher JU; Hymes K; Latkowski JA; Ødum N; Kadin ME; Ouyang Z; Geskin LJ; Smibert P; Buus TB; Koralov SB
    Blood; 2021 Oct; 138(16):1456-1464. PubMed ID: 34232982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage.
    Vasku A; Vasku JB; Necas M; Vasku V
    J Biomed Biotechnol; 2010; 2010():805907. PubMed ID: 20625418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.
    Dusílková N; Bašová P; Polívka J; Kodet O; Kulvait V; Pešta M; Trněný M; Stopka T
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
    Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
    Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.